BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 20972617)

  • 1. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
    Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
    Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis.
    Davies S; Jiang WG
    Anticancer Res; 2010 Apr; 30(4):1163-8. PubMed ID: 20530423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
    Ihnen M; Müller V; Wirtz RM; Schröder C; Krenkel S; Witzel I; Lisboa BW; Jänicke F; Milde-Langosch K
    Breast Cancer Res Treat; 2008 Dec; 112(3):419-27. PubMed ID: 18172759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.
    Tachezy M; Zander H; Gebauer F; Marx A; Kaifi JT; Izbicki JR; Bockhorn M
    J Surg Res; 2012 Sep; 177(1):e15-20. PubMed ID: 22482754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
    Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.
    Jezierska A; Olszewski WP; Pietruszkiewicz J; Olszewski W; Matysiak W; Motyl T
    Med Sci Monit; 2006 Jul; 12(7):BR245-56. PubMed ID: 16810131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
    Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
    J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients.
    Burandt E; Bari Noubar T; Lebeau A; Minner S; Burdelski C; Jänicke F; Müller V; Terracciano L; Simon R; Sauter G; Wilczak W; Lebok P
    Oncol Rep; 2014 Dec; 32(6):2628-34. PubMed ID: 25270339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
    Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
    Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation.
    Wang C; Tran-Thanh D; Moreno JC; Cawthorn TR; Jacks LM; Wang DY; McCready DR; Done SJ
    Breast Cancer Res Treat; 2011 Sep; 129(2):373-86. PubMed ID: 21046228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis.
    Witzel I; Schröder C; Müller V; Zander H; Tachezy M; Ihnen M; Jänicke F; Milde-Langosch K
    Oncology; 2012; 82(6):305-12. PubMed ID: 22555284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.
    Burkhardt M; Mayordomo E; Winzer KJ; Fritzsche F; Gansukh T; Pahl S; Weichert W; Denkert C; Guski H; Dietel M; Kristiansen G
    J Clin Pathol; 2006 Apr; 59(4):403-9. PubMed ID: 16484444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
    Minner S; Kraetzig F; Tachezy M; Kilic E; Graefen M; Wilczak W; Bokemeyer C; Huland H; Sauter G; Schlomm T
    Hum Pathol; 2011 Dec; 42(12):1946-52. PubMed ID: 21683980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
    Kilic E; Milde-Langosch K; Müller V; Wirtz R; Ihnen M
    Pathologe; 2008 Nov; 29 Suppl 2():347-52. PubMed ID: 18810438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
    Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
    Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin.
    Ihnen M; Kilic E; Köhler N; Löning T; Witzel I; Hagel C; Höller S; Kersten JF; Müller V; Jänicke F; Milde-Langosch K
    J Clin Pathol; 2011 Feb; 64(2):146-52. PubMed ID: 21262777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy.
    Jezierska A; Matysiak W; Motyl T
    Med Sci Monit; 2006 Aug; 12(8):BR263-73. PubMed ID: 16865058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleobindin 2 in human breast carcinoma as a potent prognostic factor.
    Suzuki S; Takagi K; Miki Y; Onodera Y; Akahira J; Ebata A; Ishida T; Watanabe M; Sasano H; Suzuki T
    Cancer Sci; 2012 Jan; 103(1):136-43. PubMed ID: 21988594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
    Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
    Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.